Kailera sets terms for $528.5M IPO to fund obesity assets
The biotech is raising to advance four obesity candidates licensed from Chinese developers.
TR
By Tom Reyes · Markets Editor
Apr 13 03:00 ETSource: Fierce Biotech
The wire
- 01Kailera outlined plans for a $528.5 million IPO to support a quartet of Chinese-origin obesity assets, according to Fierce Biotech.
- 02A raise of this size signals continued investor appetite for incretin and obesity programs sourced through China licensing deals.
- 03Pricing, timing and the clinical stage of each of the four candidates will determine how far the proceeds stretch.
From the source
Read at fiercebiotech.comKailera outlines plans for $528.5M IPO to support quartet of Chinese obesity assets